Pharmaceutical News

RSS

Schering-Plough reports proposed settlement in planned merger with Merck

Schering-Plough Corporation today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to enjoin the planned merger with Merck & Co., Inc., and other forms of relief.

24 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

Costly biologics drugs prompt exclusivity debate

"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.

22 Jul 2009

Some health groups increase lobbying spending, but only a slight rise overall

"Drug makers, advocacy groups, biotechnology firms and insurance companies have ratcheted up efforts to offer their two cents - and in most cases much, much more - in influencing the health care legislation now working its way through Congress," The New York Times reports.

22 Jul 2009

H1N1 death toll doubles over last month; first vaccine trial begins

The worldwide death toll from the H1N1 (swine flu) virus has doubled in the past month, reaching over 700, the WHO announced Tuesday, the AP/Google.com reports.

22 Jul 2009

Swine flu vaccine trials begin in Australia as death toll tops 700

As Australian scientists embark on the first trials of a swine flu vaccine the World Health Organisation (WHO) has announced that the H1N1 virus (swine flu) has now killed more than 700 people around the world since the outbreak began four months ago.

22 Jul 2009

New drug compound Salirasib brings hope to pancreatic cancer patients

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

20 Jul 2009

Mylan receives FDA approval for additional strengths of antipsychotic Haloperidol

Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.

20 Jul 2009

FDA approves vaccine for 2009-2010 flu season

The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.

20 Jul 2009

Genome sequencing of schistosomiasis parasites could promote drug development

Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).

16 Jul 2009

Mylan receives FDA approval for generic version of thyroid deficiency treatment Cytomel

Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

16 Jul 2009

FDA approves Onsolis pain reliever for cancer patients

The U.S. Food and Drug Administration today approved Onsolis, medication intended for certain patients with cancer to help manage breakthrough pain – severe flares of pain that break through regular pain medication.

16 Jul 2009

Scientists report new process for producing potentially safer form of acetaminophen

Scientists in Louisiana are reporting development of a process for producing large batches of a new and potentially safer form of acetaminophen, the widely used pain-reliever now the source of growing concern over its potentially toxic effects on the liver.

15 Jul 2009

Bio manufacturers poised to follow Senate victory with house win

"A veteran California lawmaker with ties to the biotechnology industry said she thinks her proposal to protect brand-name biologic makers has enough support to carry in the House Energy and Commerce Committee," Dow Jones Newswires/Wall Street Journal reports.

15 Jul 2009

GlaxoSmithKline pledges $97 million investment in AIDS drugs for Africa, allows South African drugmaker to produce generic second-line treatment

GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.

15 Jul 2009

Review of Brazil's HIV/AIDS treatment programs shows importance of generic drugs, researchers say

"Brazil has been successful in its nearly 20-year effort to treat people living with" HIV/AIDS, and generic medicines have been "a large part of the solution," according to a recent Health Affairs review, UPI reports (UPI, 7/14).

15 Jul 2009

Prevalence of artemisinin monotherapies raising risk of resistence

Almost half of all artemisinin manufacturers and malaria-endemic countries are "failing to comply" with WHO requirements to sell the treatment in combination with other drugs, which is increasing the risk that malaria parasites will develop resistance to artemsinin, Nature reports.

15 Jul 2009

Watson confirms new drug application for generic Sanctura XR

Watson Pharmaceuticals, Inc. has confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc.

15 Jul 2009

New drug blocks common cancer pathway

Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.

15 Jul 2009

HELP Committee approves protection for high tech drug companies from generics

"Senators agreed Monday to give high-tech biologic drugs 12 years of market protection before generic versions can compete," according to The Associated Press.

15 Jul 2009